Skip to main content

Advertisement

SpringerLink
Log in

Malignant thymoma: current status of classification and multimodality treatment

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Agrawal S, Datta NR, Mishra SK, Kumar S, Tandon V, Ayyagari S, Agarwal A (1999) Adjuvant therapy in invasive thymoma: an audit of cases treated over an 8 year period. Indian J Cancer 36:46–56

    CAS  PubMed  Google Scholar 

  2. Akaogi E, Ohara K, Mitsui K, Onizuka M, Ishikawa S, Mitsui T, Ogata T (1996) Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels. J Surg Oncol 63:17–22

    Article  CAS  PubMed  Google Scholar 

  3. Ariaratnam LS, Kalnicki S, Mincer F, Botstein C (1979) The management of malignant thymoma with radiation therapy. Int J Radiat Oncol Biol Phys 5:77–80

    Article  CAS  PubMed  Google Scholar 

  4. Bernatz PE, Khonsari S, Harrison EG, Jr., Taylor WF (1973) Thymoma: factors influencing prognosis. Surg Clin North Am 53:885–892

    Article  CAS  PubMed  Google Scholar 

  5. Berthaud P, Le Chevalier T, Tursz T (1990) Effectiveness of interleukin-2 in invasive lymphoepithelial thymoma. Lancet 335:1590

    Article  CAS  PubMed  Google Scholar 

  6. Bonomi PD, Finkelstein D, Aisner S, Ettinger D (1993) EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 16:342–345

    Article  CAS  PubMed  Google Scholar 

  7. Bott-Kothari T, Aron BS, Bejarano P (2000) Malignant thymoma with metastases to the gastrointestinal tract and ovary: a case report and literature review. Am J Clin Oncol 23:140–142

    Article  CAS  PubMed  Google Scholar 

  8. Buckley C, Newsom-Davis J, Willcox N, Vincent A (2001) Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 57:1579–1582

    Article  CAS  PubMed  Google Scholar 

  9. Buttgereit P, Schakowski F, Marten A, Brand K, Renoth S, Ziske C, Schottker B, Ebert O, Schroers R, Schmidt-Wolf IG (2001) Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther 8:430–439

    Article  CAS  PubMed  Google Scholar 

  10. Chen G, Marx A, Wen-Hu C, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK (2002) New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95:420–429

    Article  PubMed  Google Scholar 

  11. Ciernik IF, Meier U, Lutolf UM (1994) Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. J Clin Oncol 12:1484–1490

    Article  CAS  PubMed  Google Scholar 

  12. Curran WJ, Jr., Kornstein MJ, Brooks JJ, Turrisi AT, 3rd (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6:1722–1727

    Article  PubMed  Google Scholar 

  13. Evans WK, Thompson DM, Simpson WJ, Feld R, Phillips MJ (1980) Combination chemotherapy in invasive thymoma role of COPP. Cancer 46:1523–1527

    Article  CAS  PubMed  Google Scholar 

  14. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, Rea F, Fiorentino MV (1991) Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68:30–33

    Article  CAS  PubMed  Google Scholar 

  15. Fornasiero DO, Ghiotto C, Sartori F, Rea F, Piazza M, Fiore-Donati L, Morandi P, Aversa SM, Paccagnella A, et al. (1990) Chemotherapy of invasive thymoma. J Clin Oncol 8:1419–1423

    Article  CAS  PubMed  Google Scholar 

  16. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:814–820

    Article  CAS  PubMed  Google Scholar 

  17. Giaccone G, Musella R, Bertetto O, Donadio M, Calciati A (1985) Cisplatin-containing chemotherapy in the treatment of invasive thymoma: report of five cases. Cancer Treat Rep 69:695–697

    CAS  PubMed  Google Scholar 

  18. Goldel N, Boning L, Fredrik A, Holzel D, Hartenstein R, Wilmanns W (1989) Chemotherapy of invasive thymoma. A retrospective study of 22 cases. Cancer 63:1493–1500

    Article  CAS  PubMed  Google Scholar 

  19. Gordon MS, Battiato LA, Gonin R, Harrison-Mann BC, Loehrer PJ Sr (1995) A phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma. J Immunother 18:179–184

    Article  CAS  Google Scholar 

  20. Graeber GM, Tamim W (2000) Current status of the diagnosis and treatment of thymoma. Semin Thorac Cardiovasc Surg 12:268–277

    Article  CAS  PubMed  Google Scholar 

  21. Haniuda M, Morimoto M, Nishimura H, Kobayashi O, Yamanda T, Iida F (1992) Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 54:311–315

    Article  CAS  PubMed  Google Scholar 

  22. Hanna N, Gharpure VS, Abonour R, Cornetta K, Loehrer PJ Sr (2001) High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience. Bone Marrow Transplant 28:435–438

    Article  CAS  PubMed  Google Scholar 

  23. Harper HM, Rankin E, et al. (1991) Ifosfamide monotherapy demonstrates high activity in malignant thymoma. Proc ASCO 10:300

    Google Scholar 

  24. Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, Bryant B, Rowland C, Hodson N, Hughes J, Harper PG (1999) Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737–2744

    Article  CAS  PubMed  Google Scholar 

  25. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2000) Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 96:3872–3879

    CAS  PubMed  Google Scholar 

  26. Huhn D (2000) Thymuskarzinom und Thymom. In: Wilmanns W, Huhn D, Wilms K (eds) Internistische Onkologie. Georg Thieme, Stuttgart, pp 641–642

  27. Iwasaki Y, Kubota Y, Yokomura I, Ueda M, Hashimoto S, Arimoto T, Inaba T, Shimazaki C, Nakagawa M, Toda S (1998) Invasive thymoma successfully treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) (in Japanese). Nihon Kokyuki Gakkai Zasshi 36:288–293

    CAS  PubMed  Google Scholar 

  28. Jackson MA, Ball DL (1991) Post-operative radiotherapy in invasive thymoma. Radiother Oncol 21:77–82

    Article  CAS  PubMed  Google Scholar 

  29. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61:1948–1956

    CAS  PubMed  Google Scholar 

  30. Kirchner T, Schalke B, Buchwald J, Ritter M, Marx A, Muller-Hermelink HK (1992) Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 16:1153–1169

    Article  CAS  PubMed  Google Scholar 

  31. Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y (1994) A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44:359–367

    Article  CAS  PubMed  Google Scholar 

  32. Kosmidis PA, Iliopoulos E, Pentea S (1988) Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis. Cancer 61:1736–1740

    Article  CAS  PubMed  Google Scholar 

  33. Lara PN Jr (2000) Malignant thymoma: current status and future directions. Cancer Treat Rev 26:127–131

    Article  PubMed  Google Scholar 

  34. Lattes (1962) Thymoma and other tumors of the thymus. An analysis of 107 cases. Cancer 15:1224–1260

    Article  Google Scholar 

  35. Latz D, Schraube P, Oppitz U, Kugler C, Manegold C, Flentje M, Wannenmacher MF (1997) Invasive thymoma: treatment with postoperative radiation therapy. Radiology 204:859–864

    Article  CAS  PubMed  Google Scholar 

  36. Levine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 9:495–515

    Article  CAS  PubMed  Google Scholar 

  37. Levy Y, Afek A, Sherer Y, Bar-Dayan Y, Shibi R, Kopolovic J, Shoenfeld Y (1998) Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum 28:73–79

    Article  CAS  PubMed  Google Scholar 

  38. Leyvraz S, Henle W, Chahinian AP, Perlmann C, Klein G, Gordon RE, Rosenblum M, Holland JF (1985) Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 312:1296–1299

    Article  CAS  PubMed  Google Scholar 

  39. Loehrer PJ Sr (1999) Current approaches to the treatment of thymoma. Ann Med 31:73–79

    PubMed  Google Scholar 

  40. Loehrer PJ Sr, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15:3093–3099

    Article  CAS  PubMed  Google Scholar 

  41. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12:1164–1168

    Article  PubMed  Google Scholar 

  42. Lucchi M, Mussi A, Ambrogi M, Gunfiotti A, Fontanini G, Basolo F, Angeletti CA (2001) Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol 27:636–640

    Article  CAS  PubMed  Google Scholar 

  43. Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, Angeletti CA (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68:706–713

    Article  CAS  PubMed  Google Scholar 

  44. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E (1991) Thymoma: results of 241 operated cases. Ann Thorac Surg 51:152–156

    Article  CAS  PubMed  Google Scholar 

  45. Marino M, Muller-Hermelink HK (1985) Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch 407:119–149

    Article  CAS  Google Scholar 

  46. McKenna BP, Barnes MM, Glatstein E, Rucksdeshel JC, Weisenburger TH (1989) Malignancies of the thymus. In: Rucksdeshel JC, Weisenburger TH (eds) Thoracic oncology. WB Saunders, Philadelphia, pp 466–477

  47. Monden Y, Nakahara K, Iioka S, Nanjo S, Ohno K, Fujii Y, Hashimoto J, Kitagawa Y, Masaoka A, Kawashima Y (1985) Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg 39:165–169

    Article  CAS  PubMed  Google Scholar 

  48. Mornex F, Resbeut M, Richaud P, Jung GM, Mirabel X, Marchal C, Lagrange JL, Rambert P, Chaplain G, Nguyen TD (1995) Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys 32:651–659

    Article  CAS  PubMed  Google Scholar 

  49. Muller-Hermelink HK, Marino M, Palestro G (1986) Pathology of thymic epithelial tumors. Curr Top Pathol 75:207–268

    Article  CAS  PubMed  Google Scholar 

  50. Muller-Hermelink HK, Marx A (2000) Thymoma. Curr Opin Oncol 12: 426–433

    Article  CAS  PubMed  Google Scholar 

  51. Muller-Hermelink HK, Marx A (2000) Towards a histogenetic classification of thymic epithelial tumours? Histopathology 36:466–469

    Article  CAS  PubMed  Google Scholar 

  52. Myojin M, Choi NC, Wright CD, Wain JC, Harris N, Hug EB, Mathisen DJ, Lynch T, Carey RW, Grossbard M, Finkelstein DM, Grillo HC (2000) Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. Int J Radiat Oncol Biol Phys 46:927–933

    Article  CAS  PubMed  Google Scholar 

  53. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94:624–632

    Article  PubMed  Google Scholar 

  54. Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, Lastoria S (2002) Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94:1414–1420

    Article  CAS  PubMed  Google Scholar 

  55. Pan CC, Chen WY, Chiang H (2001) Spindle cell and mixed spindle/lymphocytic thymomas: an integrated clinicopathologic and immunohistochemical study of 81 cases. Am J Surg Pathol 25:111–120

    Article  CAS  PubMed  Google Scholar 

  56. Park HS, Shin DM, Lee JS, Komaki R, Pollack A, Putnam JB, Cox JD, Hong WK (1994) Thymoma. A retrospective study of 87 cases. Cancer 73:2491–2498

    Article  CAS  PubMed  Google Scholar 

  57. Penn CR, Hope-Stone HF (1972) The role of radiotherapy in the management of malignant thymoma. Br J Surg 59:533–539

    Article  CAS  PubMed  Google Scholar 

  58. Rea F, Sartori F, Loy M, Calabro F, Fornasiero A, Daniele O, Altavilla G (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106:543–549

    CAS  PubMed  Google Scholar 

  59. Ritter JH, Wick MR (1999) Primary carcinomas of the thymus gland. Semin Diagn Pathol 16:18–31

    CAS  PubMed  Google Scholar 

  60. Romi F SG, Aarli JA, Geilhus NE (2000) The severity of myasthenia gravis correlated with the serum concentration of titin and ryanodine receptor autoantibodies. Arch Neurol 57:1596–1600

    Article  CAS  PubMed  Google Scholar 

  61. Rosai (ed) (1999) Histological typing of tumors of the thymus. Springer, Berlin Heidelberg New York

  62. Rosenberg SA (1992) Thymic neoplasms. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 763–770

  63. Schmidt-Wolf G, Schmidt-Wolf IGH (2002) Immunomodulatory gene therapy for haematological malignancies. Br J Haematol 117:23–32

    Article  CAS  PubMed  Google Scholar 

  64. Schütte J (1995) Thymome. In: Seeber S, Schütte J (eds) Therapiekonzepte Onkologie. Springer, Berlin Heidelberg New York, pp 488–499

  65. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J (1990) Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 28:312–319

    Article  CAS  PubMed  Google Scholar 

  66. Souadjian JV, Enriquez P, Silverstein MN, Pepin JM (1974) The spectrum of diseases associated with thymoma. Coincidence or syndrome? Arch Intern Med 134:374–379

    Article  CAS  PubMed  Google Scholar 

  67. Strobel P, Helmreich M, Menioudakis G, Lewin SR, Rudiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Elert O, Semik M, Muller-Hermelink HK, Marx A (2002) Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 100:159–166

    Article  CAS  PubMed  Google Scholar 

  68. Strollo DC, Rosado-de-Christenson ML (1999) Tumors of the thymus. J Thorac Imaging 14:152–171

    Article  CAS  PubMed  Google Scholar 

  69. Suster S, Moran CA (1999) Primary thymic epithelial neoplasms: spectrum of differentiation and histological features. Semin Diagn Pathol 16:2–17

    CAS  PubMed  Google Scholar 

  70. Suster S, Moran CA (1999) Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol 111:826–833

    Article  CAS  PubMed  Google Scholar 

  71. Takahashi K, Yoshida J, Nishimura M, Nagai K (2000) Thymic carcinoma. Outcome of treatment including surgical resection. Jpn J Thorac Cardiovasc Surg 48:494–498

    Article  CAS  PubMed  Google Scholar 

  72. Thomas CR, Wright CD, Loehrer PJ (1999) Thymoma: state of the art. J Clin Oncol 17:2280–2289

    Article  CAS  PubMed  Google Scholar 

  73. Urgesi A, Monetti U, Rossi G, Ricardi U, Maggi G, Sannazzari GL (1992) Aggressive treatment of intrathoracic recurrences of thymoma. Radiother Oncol 24:221–225

    Article  CAS  PubMed  Google Scholar 

  74. van Hall T, van Bergen J, van Veelen PA, Kraakman M, Heukamp LC, Koning F, Melief CJ, Ossendorp F, Offringa R (2000) Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J Immunol 165:869–877

    Article  Google Scholar 

  75. Whooley BP, Urschel JD, Antkowiak JG, Takita H (2000) A 25-year thymoma treatment review. J Exp Clin Cancer Res 19:3–5

    CAS  PubMed  Google Scholar 

  76. Yamamoto AM GP, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ (2001) Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 59:885–890

    Article  Google Scholar 

  77. Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein A, Semik M, Muller-Hermelink HK, Marx A (2000) Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157:257–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Zhou R, Zettl A, Strobel P, Wagner K, Muller-Hermelink HK, Zhang S, Marx A, Starostik P (2001) Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 159:1853–1860

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. DeVita VT, Hellman S, Rosenberg SA (eds) (1993) Cancer principles and practice of oncology, 4th edn. Lippincott, Philadelphia, pp 763–770

  80. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492

    Article  CAS  PubMed  Google Scholar 

  81. Berruti A, Borasio P, Roncari A, Gorzegno G, Mossetti C, Dogliotti L (1993) Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 4:429–431

    Article  CAS  PubMed  Google Scholar 

  82. Dy C, Calvo FA, Mondan JP, Aparicio LA, Algarra SM, Gil A, Gonzalez F, Harguindey S (1988) Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy. J Clin Oncol 6:536–542

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Professor Dr. T. Sauerbruch, Bonn, for carefully reading our manuscript.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany

    I. G. H. Schmidt-Wolf & J. K. Rockstroh

  2. Klinik und Poliklinik für Radiologie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany

    H. Schüller

  3. Klinik und Poliklinik für Chirurgie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany

    A. Hirner

  4. Medizinische Klinik und Poliklinik II, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany

    C. Grohe

  5. Pathologisches Institut der Universität Würzburg, Würzburg, Germany

    H. K. Müller-Hermelink

  6. Charité, Campus Virchow Klinikum, Klinik für Innere Medizin mit Schwerpunkt Hämatologie-Onkologie, Humboldt-Universität zu Berlin, Berlin, Germany

    D. Huhn

Authors
  1. I. G. H. Schmidt-Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. K. Rockstroh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Schüller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Hirner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Grohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. K. Müller-Hermelink
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Huhn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. G. H. Schmidt-Wolf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt-Wolf, I.G.H., Rockstroh, J.K., Schüller, H. et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol 82, 69–76 (2003). https://doi.org/10.1007/s00277-002-0597-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-002-0597-6

Keywords

Search

Navigation